

1 **BA.4/BA.5 early surge report Austria**

2

3 Alexander Gamisch^a, Maria Elisabeth Mustafa^a

4

5 ^aDr. Mustafa, Dr. Richter Labor für medizinisch-chemische und mikrobiologische Diagnostik
6 GmbH, Abteilung Molekularbiologie, Strubergasse 20, 5020 Salzburg

7

8 **Abstract**

9 More than two years into the COVID-19 pandemic, the emergence of the Omicron subvariants
10 BA.4 and BA.5 initiated the fifth wave. BA.4/BA.5 share identical spike proteins and are thus
11 difficult to differentiate using standard diagnostic tests. The true frequency and diversity of the
12 two variants in Austria is therefore largely unknown. Aim of this report is to take stock about
13 the frequency and diversity of BA.4 & BA.5 and their subvariants based on whole genome
14 sequencing (WGS) data as deposited at GISAID database. Results show that most sequenced
15 cases belong to BA.5 (c. 86 %) rather than BA.4 (c. 14 %) and that most of the global diversity
16 (24 out of 32 subvariants) of BA.4 and BA.5 in terms of subvariants described is already present
17 in Austria. However, most cases can be attributed to a few subvariants (e.g. BA.5.1, BE.1.1,
18 BA.5.3, BA.5.2.1) with high estimated growth advantage over BA.2 (ranging 103 to 159 %) and
19 may be worth monitoring as the immediate wave unfolds.

20

21 **Introduction**

22 At the dawn of 2022, more than two years into the COVID-19 pandemic, the emergence of the
23 Omicron subvariants BA.4 and BA.5 in South Africa initiated the fifth wave (Tegally et al.
24 2022, Mohapatra et al. 2022). In Austria BA.4/BA.5 was first detected mid-May (calendar week
25 15) and became dominant within weeks in combination with rising cases numbers (AGES¹)
26 thereby dampen any hope for a “summer break” before autumn. BA.4/BA.5 carry additional
27 spike mutations (69-70del, L452R, F486V and the wild type amino acid at Q493) than BA.2
28 and are likely more transmissible than the latter due to immune evasion (Tegally et al. 2022;
29 Hoteit and Yassine 2022; Hachmann et al. 2022). BA.4/BA.5 are further hardly distinguishable
30 by PCR based screening tests and partial genome sequencing approaches that commonly target
31 the spike gene region (cf. O’Toole et al. 2022; ECDC 2022). As a corollary, the true frequency
32 and diversity of the two variants in Austria is largely unknown. Moreover, at the time of writing
33 32 more obscure subvariants of BA.4 and BA.5 have already been described². These subvariants
34 usually represent epidemiological significant clusters with a significant amount of onward
35 transmission that are defined by at least one unambiguous evolutionary event (viz. mutation;
36 Rambaut et al. 2020). Most mutations are inconsequential, but some do alter the biological
37 properties of the virus (e.g. Saito et al. 2022; Tegally et al. 2022; Hoteit and Yassine 2022;
38 Hachmann et al. 2022). Therefore, it is useful to track the frequency of the
39 mutations/subvariants when they emerge. Aim of this report is to provide an overview about
40 the frequency and diversity of BA.4 & BA.5 and their subvariants in Austria based on public
41 available whole genome sequencing (WGS) data as deposited at GISAID database (Elbe &
42 Buckland-Merrett 2017). The potential risk of these subvariants in terms of relative growth
43 advantage versus a BA.2 baseline is assessed.

44

45 **Methods**

46 A total of 1199 complete genomes of BA.4 and BA.5 collected in Austria have been
47 downloaded from GISAID (Elbe & Buckland-Merrett 2017; GISAID accessed on 08.07.22).
48 Sequences have then been classified to the Pango-nomenclatur system (Rambaut et al. 2020)
49 using the Nextclade online tool³ v.2.0.0 (Aksamentov et al. 2021) and the frequencies per
50 variant over sampling time were recorded. The Nextclade mutation profile was further used to
51 manually designate novel variants⁴ not yet recognized by the software. Finally, the

¹ <https://www.ages.at/mensch/krankheit/krankheitserreger-von-a-bis-z/coronavirus#c12422> [accessed 04.07.22]

² <https://github.com/cov-lineages/pango-designation> [accessed 04.07.22]

³ <https://clades.nextstrain.org> [accessed 08.07.22]

⁴ <https://www.pango.network/summary-of-designated-omicron-lineages/> [accessed 04.07.22]

52 Covspectrum⁵ (Chen et al. 2022) platform was used to query GISAID genomic data for global
53 variant frequencies and to calculate transmission advantage versus a BA.2 baseline following
54 Chen et al. (2021). Due to the limited number of Austrian BA.4/BA.5 genomes (n =1199; see
55 also Tab.1) the relative growth advantage per week (in percentage; 0% means equal growth) in
56 the timeframe of the last 3 months [2022-04-04 to 2022-07-04] was calculated based on
57 European genomes.

58

59 **Results and Discussion**

60 **BA.4 versus BA.5**

61 All BA.4 and BA.5 subvariants exhibit strong relative growth advantage versus BA.2 (ranging
62 between 21% and 175%; see Tab. 1) on a continental scale. For comparison, the Alpha variant
63 (B.1.1.7) exhibit a growth advantage of 43–52 % compared to the “Wild type” SARS-CoV 2
64 strain (Chen et al. 2021). However, growth advantage of BA.4 subvariants is tendentially lower
65 than those of BA.5 subvariants (Tab.1). Consequently, albeit BA.4 initially was more frequent
66 in Austria than BA.5 the proportion has shifted in favor of BA.5 in recent weeks (around
67 calendar week 17) (Fig.1). Now, in concordance with the global trend, the BA.5 variant is
68 dominant with c. 86 % (1035/1199) compared to BA.4 (c. 14 % (164/1199) in Austria (Fig.1).

69

70 **BA.4/BA5 subvariants**

71 From the 32 subvariants of BA.4/BA5 a total of 24 subvariants were already detected in Austria
72 over the past 12 weeks (calendar week 15 to 26) (Fig.1, Fig.2) likely due to multiple
73 independent introductions of the different strains. In Austria, the top five most frequently
74 sequenced subvariants over the whole timeframe are BA.5.1, BE.1.1, BA.5.3, BA.5.2.1 and
75 BA.5 thereby representing a total of c. 68 % of cumulative cases sequenced. Of those BA.5.1,
76 BE.1.1 and BA.5.2.1 show signs of sustained growth whereas BA.5.3 apparently peaked in
77 calendar week 19 and is on decline ever since. The top five subvariants with the highest growth
78 advantage (ranging between 175 and 151 %) are BA.5.1.2, BE.1, BE.1.1, BA.5.6, BA.5.2.3
79 whereas three of those (BA.5.6, BA.5.2.3, BA.5.1.2) are only known from a handful of recent
80 cases in Austria so far (Tab.1, Fig. 3). The variants BE.1.1, BA.5.2.1, BA.5.1 on the other hand
81 appear to be more successful than their peers when judged by cases numbers and estimated
82 growth advantages (Tab.1, Fig. 3) and may be worth monitoring as the proximate wave unfolds.

83

84

⁵ <https://cov-spectrum.org> [accessed 04.07.22]

85 **Acknowledgements**

86 We gratefully acknowledge all data contributors, i.e. the authors and their originating
87 laboratories responsible for obtaining the specimens, and their submitting laboratories for
88 generating the genetic sequence and metadata and sharing via GISAID. Following labs
89 submitted to GISAID: Bergthaler laboratory, CeMM Research Center for Molecular Medicine
90 of the Austrian Academy of Sciences; Lifebrain Covid Labor GmbH; Dr. Mustafa, Dr. Richter
91 Labor für medizinisch-chemische und mikrobiologische Diagnostik GmbH, Abteilung
92 Molekularbiologie; Center for Virology, Medical University of Vienna; Institute of Virology
93 Department of Hygiene, Microbiology and Public Health at Innsbruck Medical University.

94

95

96

97

98

99 **References**

- 100 Aksamentov, I., Roemer, C., Hodcroft, E. B., & Neher, R. A. (2021). Nextclade: clade
101 assignment, mutation calling and quality control for viral genomes. *Journal of Open Source*
102 *Software*, 6(67), 3773.
- 103
- 104 Chen, C., Nadeau, S. A., Topolsky, I., Manceau, M., Huisman, J. S., Jablonski, K. P., ... &
105 Stadler, T. (2021). Quantification of the spread of SARS-CoV-2 variant B. 1.1. 7 in
106 Switzerland. *Epidemics*, 37, 100480.
- 107
- 108 Chen, C., Nadeau, S., Yared, M., Voinov, P., Xie, N., Roemer, C., & Stadler, T. (2022). CoV-
109 Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new
110 variants. *Bioinformatics*, 38(6), 1735-1737.
- 111
- 112 Elbe, S., & Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative
113 contribution to global health. *Global challenges*, 1(1), 33-46.
- 114
- 115 European Centre for Disease Prevention and Control (ECDC). Implications of the emergence
116 and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA – 14
117 June 2022. ECDC: Stockholm; 2022.
- 118
- 119 Hachmann, N. P., Miller, J., Collier, A. R. Y., Ventura, J. D., Yu, J., Rowe, M., ... & Barouch,
120 D. H. (2022). Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12. 1, BA.
121 4, and BA. 5. *New England Journal of Medicine*. 387, 86-88.
- 122
- 123 Hoteit, R., & Yassine, H. M. (2022). Biological Properties of SARS-CoV-2 Variants:
124 Epidemiological Impact and Clinical Consequences. *Vaccines*, 10(6), 919.
- 125
- 126 Mohapatra, R. K., Kandi, V., Sarangi, A. K., Verma, S., Tuli, H. S., Chakraborty, S., ... &
127 Dhama, K. (2022). The recently emerged BA. 4 and BA. 5 lineages of Omicron and their
128 global health concerns amid the ongoing wave of COVID-19 pandemic–Correspondence.
129 *International Journal of Surgery* (London, England), 103, 106698.
- 130

131 O'Toole, Á., Pybus, O. G., Abram, M. E., Kelly, E. J., & Rambaut, A. (2022). Pango lineage
132 designation and assignment using SARS-CoV-2 spike gene nucleotide sequences. *BMC*
133 *genomics*, 23(1), 1-13.

134

135 Rambaut, A., Holmes, E. C., O'Toole, Á., Hill, V., McCrone, J. T., Ruis, C., ... & Pybus, O.
136 G. (2020). A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
137 epidemiology. *Nature microbiology*, 5(11), 1403-1407.

138

139 Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., ... & de
140 Oliveira, T. (2022). Continued emergence and evolution of Omicron in South Africa: New
141 BA. 4 and BA. 5 lineages. *medRxiv*.

142


143 Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., ... & Sato, K. (2022).
144 Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. *Nature*,
145 602(7896), 300-306.

146

147

148 **Figures**

149



150

151 **Figure 1. Omicron subvariants BA.4 and BA.5 genomes over time (calendar weeks) in Austria. A, BA.4 and BA.5 including subvariants over**

152 **time. B, subvariants of BA.4 and BA.5 over time.**

153

154


155

156 **Figure 2. Heatmap of number BA.4 and BA.5 genomes over time (between calendar**
 157 **week 15 and 26) in Austria**

	calendar week											
	15	16	17	18	19	20	21	22	23	24	25	26
BA.4	0	2	0	2	1	7	2	2	4	16	10	10
BA.4.1	0	0	0	1	1	8	6	0	3	11	5	6
BA.4.1.1	0	0	0	4	3	4	4	0	2	1	0	0
BA.4.1.2	0	12	3	3	0	14	4	1	0	2	1	1
BA.4.2	0	0	0	0	0	0	0	0	0	1	0	0
BA.4.4	1	1	1	0	0	1	0	1	1	0	1	0
BA.5	0	0	0	1	1	0	1	0	44	11	4	16
BA.5.1	0	0	1	2	5	26	48	11	50	68	60	86
BA.5.1.2	0	0	0	0	0	0	0	0	1	0	2	0
BA.5.1.3	0	0	0	0	0	2	2	0	1	1	3	4
BA.5.2	0	0	0	0	0	3	0	1	7	20	21	26
BA.5.2.1	0	0	0	2	0	6	5	2	1	24	28	38
BA.5.2.3	0	0	0	0	0	0	0	0	0	1	1	0
BA.5.3	0	2	2	24	30	19	20	2	7	2	3	1
BA.5.3.1	0	0	0	0	0	1	0	0	0	3	1	1
BA.5.3.2	0	0	1	1	0	1	5	0	0	2	0	1
BA.5.3.3	0	0	0	0	0	0	0	0	0	1	0	1
BA.5.3.4	0	0	0	0	0	0	0	0	0	0	1	0
BA.5.5	0	0	0	0	0	0	1	1	1	2	2	5
BA.5.6	0	0	0	0	0	0	0	1	0	1	0	3
BE.1	0	0	0	3	2	8	8	0	5	8	7	14
BE.1.1	0	0	2	1	0	0	8	1	15	53	46	37
BF.1	0	0	0	0	1	5	2	0	1	8	2	10
BF.3	0	0	0	0	0	0	0	0	0	2	0	0

158

159



160

161 **Figure 3. Subvariant growth advantage vs. BA.2 and genomes number**

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180 **Tables**

181 **Table 1. BA.4 and BA.5 subvariants, frequency, associated mutations, genome frequency global and in Austria as well as growth advantage**
 182 **versus BA.2 based on genomic sequencing data.**

Subvariant	Initial predominant countries ^a	Associated mutation(s) ^a	Global ^b	Austria	Current adv. per week (%) ^b	Conf. int. (%) ^b
BA.4	South Africa	parental lineage	26452*	164*	93%	91-95%
BA.4.1	South Africa	T21570G (S:V3G)	16194*	41	84%	82-87%
BA.4.1.1	South Africa and Germany	A23570G (S:I670V)	938	18	76%	69-83%
BA.4.1.2	Austria	C3176T (Orf1a:P971S)	168	41	21%	14-27%
BA.4.1.3	Israel	A2435G (Orf1a:R724G)	122	0	NA	NA
BA.4.1.4	Israel	G25266T (S:C1235F)	320	0	NA	NA
BA.4.2	USA	C5173A (Orf1a:H1636Q)	767	1	107%	84-130%
BA.4.3	Israel	C21365T (Orf1b:P2633L)	169	0	72%	37-106%
BA.4.4	USA	C25708T (Orf3a:L106F)	1491	7	101%	92-111%
BA.4.5	Australia	G22104A (S:G181E)	154	0	NA	NA
BA.5	South Africa	parental lineage	65951*	1035*	112%	111-114%
BA.5.1	Portugal	C29666T (ORF10:L37F)	23037*	357	103%	102-105%
BA.5.1.1	USA	C25672A (Orf3a:L94I)	806	0	NA	NA
BA.5.1.2	Europe	G27214A (Orf6:V5I)	270	3	151%	131-172%
BA.5.1.3	Germany Portugal and Spain	G22427A (S:V289I)	709	13	114%	105-122%
BA.5.2	South Africa, England and USA	A28330G (ORF9b:D16G)	21221*	78	133%	130-136%
BA.5.2.1	South Africa, England and USA	A27038G (ORF5:T172T)	12918	106	125%	122-128%
BA.5.2.2	France, Martinique	G20356A (Orf1b:G2297S)	257	0	85%	74-96%
BA.5.2.3	UK	G625T (Orf1a:K120N)	334	2	175%	154-196%
BF.1	England, Denmark, Spain and Scotland	G21520T (Orf1ab:V7086F) (Orf1b:2685F)	1944*	0	90%	85-94%
BF.1.1	USA	G10835A (Orf1a:V3524I)	191	29	75%	41-109%
BF.2	Denmark	G14398T (Orf1b:V311L)	260	2	122%	106-137%
BF.3	India	C23202T (S:T547I)	137	0	NA	NA
BF.4	England	A22337G (S:T259A)	248	0	134%	115-153%
BA.5.3	Germany and South Africa	C1931A (ORF1ab:Q556K)	10338*	112	105%	103-108%

BA.5.3.1	South Africa, Austria and England	G28681T (N:E136D)	1933	6	150%	145-154%
BA.5.3.2	Germany	G621A (ORF1ab:R119H)	784	11	67%	62-71%
BA.5.3.3	UK	C6843T (Orf1a:S2193F)	369	2	118%	105-130%
BA.5.3.4	Germany	G20718T (Orf1b:M2417I)	267	1	64%	56-71%
BE.1	South Africa, Austria and England	G16935A (ORF1b:M1156I)	7321*	55	154%	149-159%
BE.1.1	Germany	C11750T (Orf1a:L3829F)	3817	163	159%	153-165%
BE.2	Belgium	C2910T (Orf1a:T882I)	110	0	66%	53-80%
BA.5.5	USA	C21789T (S:T76I)	6417	12	142%	127-157%
BA.5.6	USA	C17402T (Orf1b:A1312V)	1831	5	169%	144-194%

183 ^a<https://www.pango.network/summary-of-designated-omicron-lineages/> [accessed 04.07.22]

184 ^b<https://cov-spectrum.org> [accessed 04.07.22]

185 *including subvariants

186

187

188

189

190

191

192

193

194

195

196

197

198

199